• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BioArctic (OM:BIOA B) Could Be 7% Undervalued Following Royalty Driven Optimism

    Simply Wall St·10/08/2026 12:28:19
    Listen to the news

    BioArctic (OM:BIOA B) has been back in focus after recent trading saw the share price close at SEK 295.4. Investors are weighing this valuation against mixed short term and longer term return figures.

    Recent trading has been choppy for BioArctic, with the share price down 2.25% over the last session and about 10% lower over the past month. However, the 5 year total shareholder return of 110.45% still points to a very different long run experience for investors.

    Spot opportunities that rhyme with BioArctic's recent swings by scanning our hand picked 225 resilient stocks with low risk scores, which aims to pair steadier profiles with room for upside.

    BioArctic now trades near SEK 295 after a choppy spell that erased some gains but left longer term holders ahead. Does that reset leave more upside potential than downside risk for new buyers?

    Most Popular Narrative: 7% Undervalued

    On the most followed view of BioArctic, a fair value of SEK316.75 sits modestly above the last close at SEK295.4. This frames the current pullback as a relatively small valuation gap rather than a wholesale reset.

    Recent record quarterly royalties, new milestone inflows (e.g., European regulatory milestone, Novartis upfront), and exceptionally robust cash balances may be leading investors to believe that future earnings will remain elevated or further accelerate, driving overvaluation relative to normalized, long-term profit trends.

    See why 19 investors see BioArctic as 7% undervalued.

    Result: Fair Value of SEK316.75 (UNDERVALUED)

    Still, the BioArctic story could shift quickly if Leqembi underperforms expectations, or if fresh safety or reimbursement setbacks cool current optimism.

    Find out about the key risks to this BioArctic narrative.

    Another Take On BioArctic’s Valuation

    The fair value narrative presents BioArctic as modestly undervalued, yet the price tag tells a different story. On a P/S basis of 26.1x versus a Swedish Biotechs average of 12.2x and a fair ratio of 14.7x, the stock appears richly priced. Is this a cushion of quality or a valuation stretch that could compress?

    For a closer look at how these pricing gaps compare with peers and that fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

    OM:BIOA B P/S Ratio as at Oct 2026
    OM:BIOA B P/S Ratio as at Oct 2026

    Next Steps

    Mixed messages on BioArctic can pull you in both directions, so move quickly, test the numbers yourself, and weigh the trade off between its 1 key reward and 1 important warning sign 1 key reward and 1 important warning sign

    Looking for more investment ideas beyond BioArctic?

    Do not stop with BioArctic. Use this valuation check as a springboard and line up a watchlist that actually fits your goals before the next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.